Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 May;43(13):1597-1609.
doi: 10.1200/JCO-24-01730. Epub 2025 Feb 18.

Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

Doris K Hansen  1 , Lauren C Peres  1 , Danai Dima  2 , Alicia Richards  1 , Leyla Shune  3 , Aimaz Afrough  4 , Shonali Midha  5 , Binod Dhakal  6 , Mehmet H Kocoglu  7 , Shebli Atrash  8 , Christopher Ferreri  8 , Omar Castaneda  1 , James A Davis  9 , Evguenia Bhurtel  3 , Joseph McGuirk  3 , Charlotte Wagner  10 , Radhika Bansal  11 , Patrick Costello  5 , Kinaya Smith  6 , Alex Lieberman-Cribbin  12 , Gabriel De Avila  1 , Sneha Purvey  13 , Hitomi Hosoya  14 , Lekha Mikkilineni  14 , Laura B Oswald  1 , Gurbakhash Kaur  4 , Oren Pasvolsky  15 , Mahmoud Gaballa  15 , Megan M Herr  16 , Peter Forsberg  17 , Murali Janakiram  18 , Myo Htut  18 , Sireesha Asoori Maringanti  19 , Nilesh Kalariya  15 , Hamza Hashmi  20 , Ran Reshef  21 , Douglas W Sborov  10 , Omar Nadeem  5 , Faiz Anwer  22 , Jack Khouri  22 , Shahzad Raza  22 , Djordje Atanackovic  7 , Melissa Alsina  1 , Ciara L Freeman  1 , Frederick L Locke  1 , Peter Voorhees  8 , Larry D Anderson Jr  4 , Shambavi Richard  12 , Thomas Martin  19 , Yi Lin  11 , Krina K Patel  15 , Surbhi Sidana  14 ; US Multiple Myeloma Immunotherapy Consortium
Affiliations
Comparative Study

Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

Doris K Hansen et al. J Clin Oncol. 2025 May.

Erratum in

  • Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.
    Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, Midha S, Dhakal B, Kocoglu MH, Atrash S, Ferreri C, Castaneda O, Davis JA, Bhurtel E, McGuirk J, Wagner C, Bansal R, Costello P, Smith K, Lieberman-Cribbin A, De Avila G, Purvey S, Hosoya H, Mikkilineni L, Oswald LB, Kaur G, Pasvolsky O, Gaballa M, Herr MM, Forsberg P, Janakiram M, Htut M, Maringanti SA, Kalariya N, Hashmi H, Reshef R, Sborov DW, Nadeem O, Anwer F, Khouri J, Raza S, Atanackovic D, Alsina M, Freeman CL, Locke FL, Voorhees P, Anderson LD Jr, Richard S, Martin T, Lin Y, Patel KK, Sidana S; US Multiple Myeloma Immunotherapy Consortium. Hansen DK, et al. J Clin Oncol. 2025 Apr 10;43(11):1399. doi: 10.1200/JCO-25-00453. Epub 2025 Mar 7. J Clin Oncol. 2025. PMID: 40053892 No abstract available.

Abstract

Purpose: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). We compare safety, efficacy, and survival among patients with RRMM treated with standard-of-care (SOC) ide-cel or cilta-cel.

Methods: Data were from a retrospective chart review of patients with RRMM leukapheresed by December 31, 2022, with the intent to receive SOC ide-cel or cilta-cel at 19 institutions. An inverse probability of treatment weighting (IPTW) approach was used to compare outcomes by therapy type.

Results: A total of 641 patients were leukapheresed by December 31, 2022, with ide-cel (n = 386) and cilta-cel (n = 255). Five hundred eighty-six patients were infused (n = 350 for ide-cel; n = 236 for cilta-cel) with a median follow-up of 12.6 and 13.0 months for ide-cel and cilta-cel, respectively. After IPTW, patient characteristics were well balanced. Cilta-cel was associated with higher likelihood of grade ≥3 cytokine release syndrome (CRS; odds ratio [OR], 6.80 [95% CI, 2.28 to 20.33]), infections (OR, 2.03 [95% CI, 1.41 to 2.92]), second primary malignancies (OR, 1.77 [95% CI, 0.89 to 3.56]), and delayed neurotoxicity (OR, 20.07 [95% CI, 4.46 to 90.20]). Cilta-cel was also associated with better treatment responses (≥complete response: OR, 2.42 [95% CI, 1.63 to 3.60]), longer progression-free survival (hazard ratio [HR], 0.48 [95% CI, 0.36 to 0.63]), and longer overall survival (HR, 0.67 [95% CI, 0.46 to 0.97]). No associations were observed between therapy type and immune effector cell-associated neurotoxicity syndrome, any CRS, severe cytopenia at days 30 and 90, or nonrelapse mortality. We observed consistent findings when repeating the analyses restricting the ide-cel cohort to patients infused during the same time period as Food and Drug Administration approval for cilta-cel (≥March 2022).

Conclusion: Cilta-cel demonstrated superior efficacy and survival, with higher incidence of certain toxicities, compared with ide-cel.

PubMed Disclaimer

Conflict of interest statement

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

D.K.H reports research funding from Bristol-Myers Squibb, Karyopharm, Kite Pharma, and Adaptive Biotech; Consulting or advisory role for Bristol Myers Squibb, Janssen, Legend Biotech, Pfizer, Kite Pharma, and Karyopharm. L.C.P reports research funding from Bristol Myers Squibb and Karyopharm. A.A reports research funding from Abbvie, Adaptive Biotech, K36 Therapeutics; Consulting or advisory role for Karyopharm, Bristol Myers Squibb, and Sanofi. S.M reports consulting or advisory role with Janssen and Pfizer. B.D reports consulting or advisory role for Bristol Myers Squibb, Janssen, Genentech. Kite Pharma, Pfizer, Arcellx, Karyopharm, ECor1, Takeda, and Natera; research funding from Bristol Myers Squibb, Janssen, Arcellx, Carsgen, C4 therapeutics, and Sanofi. S.A reports honoraria from Janssen; Research funding from GlaxoSmithKline, Amgen, Karyopharm Therapeutics, Janssen, Bristol Myers Squibb; Honoraria from Janssen. C.F reports consulting or advisory role for Sanofi and Janssen; Stock/other ownership in Affimed Therapeutics. O.C reports consulting or advisory role for Bristol Myers Squibb, Janssen, and Legend Biotech. J.A.D reports consulting or advisory role for Janssen. J.M reports honoraria from Kite Pharma, Juno Therapeutics, Allovir, Magenta Therapeutics, and EcoR1 Capital; Speakers’ bureau for Kite/Gilead; Research funding from Novartis, Fresenius Biotech, Astellas Pharma, Bellicum Pharmaceuticals, Novartis, Gamida Cell, Pluristem Therapeutics, Kite Pharma, and AlloVir; Honoraria from Kite, AlloVir, Juno Therapeutics, and Magenta Therapeutics; Travel, accommodations, expenses from Kite Pharma. R.B reports travel support from Kite Pharma. L.M reports consulting or advisory role for Legend Biotech and BioLineRx. G.K reports consulting or advisory role for Bristol Myers Squibb, Cellectar, Sanofi, Janssen, and Arcellx, and research funding from Bristol Myers Squibb, Janssen, and Arcellx. M.J reports consulting or advisory role for Bristol Myers Squib, Janssen, and Legend Biotech; research funding from Bristol Myers Squib, Janssen, and Fate Therapeutics. H.H reports consulting or advisory role for Janssen, Amgen, and Karyopharm. R.R reports consulting or advisory role with Allogene, Gilead Sciences, Incyte, TScan, Orca Bio, Quell Biotherapeutics, Sana Biotechnology and Autolus, expert witness role with Bayer, and research funding from Atara Biotherapeutics, Incyte, Sanofi, Immatics, Abbvie, TCR2, Takeda, Gilead Sciences, CareDx, TScan, Cabaletta, Synthekine, Bristol Myers Squibb, J&J, Genentech and Precision Biosciences. D.W.S reports consulting or advisory role for Sanofi, GlaxoSmithKline, Bristol Myers Squibb, Legend Biotech, Janssen, Pfizer, Bioline, AstraZeneca, Arcellx and Abbvie. O.N reports consulting or advisory role with Bristol Myers Squibb, Janssen, Takeda, Sanofi, Pfizer, GPCR therapeutics, and research funding from Janssen and Takeda. F.A reports consulting or advisory role for Bristol Myers Squibb, Celgene, Caribou biosciences; Research funding from Allogene Therapeutics, Celgene, GlaxoSmithKline, Bristol Myers Squibb, and Caribou Biosciences. J.K reports research funding from Prothena, Ascentage, Janssen, Karyopharm, and GPCR Therapeutics; consulting or advisory role for GPCR Therapeutics, Janssen, Prothena, and Legend Biotech. S.R reports consulting or advisory role for Prothena Biosciences, Pfizer, and Kite Pharma. M.A reports consulting or advisory role for Bristol Myers Squibb and Janssen; Speakers’ bureau for Janssen; Honoraria from Janssen. C.L.F reports Honoraria/consulting Bristol Myers Squibb, Seattle Genetics, Celgene, Abbvie, Sanofi, Incyte, Amgen, and ONK therapeutics & Janssen; research funding from Bristol Myers Squibb, Janssen and Roche/Genentech. F.L.L reports a consulting or advisory role for Allogene, Amgen, Bluebird Bio, Bristol Myers Squibb/Celgene, Calibr, Cellular Biomedicine Group, Cowen, ecoR1, Emerging Therapy Solutions Gerson Lehman Group, GammaDelta Therapeutics, Iovance, Janssen, Kite, a Gilead Company, Legend Biotech, Novartis, Umoja, and Wugen; research funding from Allogene, Kite, and Novartis; and patents, royalties, other intellectual property in the field of cellular immunotherapy. P.V reports consulting or advisory role for Abbvie, AstraZeneca, Karyopharm Therapeutics, Bristol Myers Squibb, Lava Therapeutics, Sanofi, Janssen, GlaxoSmithKline; Research funding from Abbvie, Janssen, GlaxoSmithKline, and TeneoBio; Travel, accommodations, and expenses from Sanofi. L.D.A Jr reports honoraria and membership on an entity’s Board of Directors or advisory committees for Bristol Myers Squibb, Celgene, GSK, AbbVie, Karyopharm, Janssen, Prothena, Sanofi, Beigene, Cellectar, and Amgen. T.M reports research funding from Sanofi, Amgen, and Janssen Oncology; Consulting or advisory role for GlaxoSmithKline, Legend Biotech. Y.L reports consultancy fees from Janssen, Juno, Vineti, Kite/Gilead, Novartis, Legend, Sorrento, Gamida Cell, Celgene, Bluebird Bio, and research funding from Janssen, Kite/Gilead, Merck, Celgene, Bluebird Bio, and Takeda. K.K.P reports consulting or advisory role for Bristol Myers Squibb, Janssen, Pfizer, Arcellx, and Karyopharm Therapeutics; Research funding from Bristol Myers Squibb, Poseida Therapeutics, Takeda, Janssen, Cellectis, Nektar, Abbvie/Genentech, Precision Biosciences, and Allogene Therapeutics; Travel, accommodations, and expenses from Bristol Myers Squibb. S.S reports consulting or advisory role for Janssen, Bristol Myers Squibb, Legend, Magenta Therapeutics, Sanofi, Pfizer, Takeda, Kite, Abbvie, Regeneron, BiolineRx, Genentech/Roche; Research funding from Janssen, Magenta Therapeutics, Allogene Therapeutics, Novartis and Bristol Myers Squibb. Remaining authors with no potential conflicts of interest.

References

    1. van de Donk NWCJ, Pawlyn C, Yong KL: Multiple myeloma. Lancet Lond Engl 397:410–427, 2021 - PubMed
    1. Nijhof IS, van de Donk NWCJ, Zweegman S, et al.: Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update. Drugs 78:19–37, 2018 - PMC - PubMed
    1. Sonneveld P, Broijl A: Treatment of relapsed and refractory multiple myeloma. Haematologica 101:396–406, 2016 - PMC - PubMed
    1. Munshi NC, Anderson LD, Shah N, et al.: Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med 384:705–716, 2021 - PubMed
    1. San-Miguel J, Dhakal B, Yong K, et al.: Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med 389:335–347, 2023 - PubMed